Actuate Therapeutics Sees Market Cap Slide, Private Equity Backers Feel the Pinch
A sharp decline in Actuate Therapeutics' market valuation last week has disproportionately impacted its major private equity shareholders, who control a dominant stake in the biopharmaceutical firm. The stock's recent performance puts a spotlight on ownership structure and its influence on risk.